Eclipse Diagnostics

MedTech Device To Monitor Stroke Risk

Company Information

Website:

http://www.eclipsedx.com/

Sector:

Medical Devices & Equipment

Location:

​Los Angeles, CA

Eclipse Diagnostics is a medical technology company. It's developing an at-home test to monitor the risk of strokes.

The company is targeting the global stroke management market — projected to reach $36 billion by 2023 — and aims to receive FDA approval for its device in three years.

Stroke is the second leading cause of death worldwide, accounting for 6 million deaths each year.

A stroke occurs when blood flow to an area of the brain is cut off. When this happens, brain cells are deprived of oxygen and begin to die. When brain cells die during a stroke, abilities controlled by that area such as memory and muscle control are lost.

Effects of a stroke depend on the length and severity of the event, and can range from temporary weakness of an arm or leg to paralysis.

In the U.S., 800,000 people suffer a stroke each year. And 25% of those strokes are recurrent.

While the risk of stroke can be reduced by measures including lowering blood pressure, losing weight, and treating conditions like diabetes and atrial fibrillation, there is currently no way to assess and monitor the risk of stroke at home.

Eclipse Diagnostics is changing that fact. Its home testing device measures a heart failure blood marker that, when elevated, indicates a high risk of stroke. A weakened heart cannot pump blood efficiently, which can lead to the formation of blood clots that can cause a stroke.

Here’s how the device works:

The device is an at-home blood test, similar to glucose tests used by patients with diabetes.

The test requires only a drop of blood, which is put onto a disposable, one-time test strip. The strip is then inserted into Eclipse’s handheld test reader.

The reader connects via Bluetooth to a smartphone and sends the data to the corresponding Eclipse mobile app in 15 minutes. The mobile app analyzes the data and alerts the user if he/she needs to visit the doctor.

By conducting these tests on a weekly basis, users can receive early warning signs of a stroke and take action.

It should be noted, however, that this device is not intended to prevent or reverse signs of a stroke.

Eclipse offers users three ways to use (and pay for) its device:

Casual — this costs $60 per month and comes with the device, mobile app, and 4 testing strips.

Basic — this costs $99 per month and comes with the device, mobile app, and 8 testing strips.

Monitor+ — this costs $160 per month and comes with the device, mobile app, and 15 testing strips.

The technology behind Eclipse's device was developed in 2010 by Robert Marks, a professor at the Ben-Gurion University in Israel. The technology was further developed in Singapore with funding from the Singapore-MIT Alliance for Research and Technology.

From those developments, Marks and Dr. Luka Fajs founded Biosensorix in November 2015. Over the next two years, the company completed its first prototype and, in February 2018, switched its name to Eclipse Diagnostics.

Team Background

Robert Marks - Co-Founder & Chief Scientist

For 23 years, Robert has served as a professor at Ben-Guion University in Israel, in the school’s department of Biotechnology Engineering.

During his time as a professor, he co-founded Polyrizon, an early-stage healthcare company focused on biotechnology.

He has published more than 150 papers and received four patents for his work in the biotechnology field.

Robert earned a Bachelor’s degree in Biological Sciences from UC Santa Barbara, a Master’s in Physiology from UC Santa Barbara, and a Ph.D. in Immunology from the Weizmann Institute of Science.

Luka Fajs - Co-Founder & CEO

Before starting Eclipse/Biosensorix, Luka served as a research fellow at Nanyang Technological University in Singapore.

In addition, he spent time as a researcher at the University of Ljubljana’s Institute of Microbiology and Immunology.

Luka earned a Bachelor’s degree and Ph.D. in Microbiology from the University of Ljubljana.

Co-Investors

Raising
$1.07 million
Committed
$149.9K (14%)
Current Valuation
$10.1 million
Min. Investment
$500
Deal Type
Title III
(For all investors)
Offering Type
Equity
Finance History
Notable Investors
Learn more on Start Engine